Gentamycin
Spina Bifida
Medstar Health Research InstituteEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Spina Bifida cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Lactobacillus Rhamnosus Gg Medstar Health Research Institute | Early Phase 1 | C |
Metformin Universitaire Ziekenhuizen KU Leuven | N/A | D |
Same molecule, other indications
Gentamycin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →